Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
medical treatment
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
  news and events  
HOME >> MEDIA >> Govt likely to cap retail price of swine flu drug
Pharmaceuticals Industry News :  

 

Govt likely to cap retail price of swine flu drug

THE government may cap the retail price of anti-viral drug oseltamivir used for the treatment of swine flu if market competition does not force the price down, a senior official in the ministry of chemicals and fertilizers said.
    The pharma industry, however, defended the pricing — ranging from Rs 450 to Rs 800 for a five-day course — as reasonable considering the shortage of the raw material.
    “If prices do not behave for themselves than we will have to intervene,” the government official said on condition of anonymity.
    India reported 150 fresh cases of swine flu on Tuesday.
    Chemists said there is a near-monopoly scene in the market despite the launch of the drug by Natco Pharma, Hetero Drugs and Strides Arcolab. The only product available with most of the licensed chemists is Hetero’s brand Fluvir, said Pradeep Singh of New Delhi Medicos (a licensed chemist for selling oseltamivir) and member of All India Organisation of Chemists and Druggists.
    Currently, a strip of 10 tablets of Hetero’s Fluvir cost Rs 449 while Cipla’s Virenza is priced at around Rs 800 for a pack of 20 rotacaps (powdered medication stored in a capsule) along with an inhaler. Natco Pharma has launched its brand Natflu at a price of Rs 480 for a bottle of 10 capsules.
    A Natco official said the retail price includes excise component along with margins for distribution and stockists. “The price of the raw material also keeps fluctuating, and at times, there is little raw material available,” he said.
    While the open market prices remain high, the government procurement price of oseltamivir has come down substantially from Rs 343 to Rs 260 for 10 tablets since the outbreak of the disease in India.
    The lack of acceptance of second line drugs is also partly responsible for low visibility of the drug. According to Mr Singh of New Delhi Medicos, a second line drug Zanamivir, sold under Cipla’s brand Virenza, is available but the demand is only for the first line drugs.
    The government is also exploring the possibility of involving the public sector to manufacture the formulation as well as the bulk drug required for the medicine.
    Meanwhile, the country’s top drug regulator Drug Controller General of India (DCGI) has asked four multinational drug makers — Baxter, Novartis, Sanofi Aventis and Glaxosmithkline (GSK) — to submit detailed dossiers for safety and efficacy review of their vaccines for swine flu.
    “The companies will soon start their bridge tests of the vaccine on around 300 people in India under the supervision of Indian Council of Medical Research,” DCGI Dr Surinder Singh said. The DCGI will approve protocol for the study after reviewing the dossiers.
    According to health ministry estimates, so far 65,803 people have been tested for swine flu in various government and private laboratories across the country. Out of this, 12,334 people have been found positive. India has reported 399 deaths due to swine flu till Wednesday evening.
BAD TASTE
Government to take the steps if market competition does not force the price down
Pharma industry defended the pricing as reasonable considering the shortage of the raw material
Chemists say there is near-monopoly scene in the market
Govt also exploring the possibility of involving the public sector to manufacture the formulation as well as the bulk drug required for the medicine
 

 

 


Growing Stronger, Growing
Better
research lab

pharma news
 

 
 
 


 

 

            
 Print page   Send by mail

 

 

 

 

   
   
MEDIA TAJ
 
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

`  

 

 

 

 

 

 

 

 

 

 

 
 www.tajpharma.com

   

 

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement
Note: The pharmaceuticals Industry news provided on the web site is not for claiming usage and is just to provide information to users